Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II
A Double-Blind, Placebo-Controlled Trial of Seroquel for the Treatment of Dysphoric Hypomania in Bipolar II Patients
Sponsor: AstraZeneca
A PHASE4 clinical study on Bipolar II Disorder, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2008. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Oct 2017 [monthly]
Completed PHASE4
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .